14.00-15.30 - How should we protect babies against GBS now and in the future?
Chair Prof Paul Heath, St George’s University of London
GBS is estimated to kill 90,000 babies and could be responsible for as many as 3.5 million preterm births and 60,000 stillbirths around the world every year, but no vaccine is available to prevent it. What are the prospects for a vaccine, and what strategies should be used meanwhile to protect mothers and babies against GBS?
15.30-17.00 - What strategies will help to control the rise of non-vaccine-preventable pneumococcal disease and pneumococcal meningitis
Chair Professor Adam Finn, University of Bristol
- Testing vs risk-based antibiotic prophylaxis in pregnancy: where are we at? Dr Kate Walker, University of Nottingham
- Rapid GBS testing for women in labour. Prof Jane Daniels, University of Nottingham
- What expectant parents want. Jane Plumb, GBSSupport
- Update on progress towards a GBS vaccine and pathway to licensure. Prof Kirsty le Doare, SGUL
- Impact of GBS on long-term cognitive outcomes. Prof Joy Lawn, LSHTM
There has been tremendous progress in preventing pneumococcal disease around the world - as of June 2020, 146 countries had introduced pneumococcal conjugate vaccine (PCV) into their national immunisation programmes. But in some countries that were early adopters of PCV, the number of non-vaccine-preventable pneumococcal cases is of concern. In older adults in the UK, for example, levels are nearly as high as we saw with vaccine preventable strains before vaccines were introduced.
Click here to download these agendas and speaker biographies as a PDF.
- Impact of PCV on invasive pneumococcal disease across the age spectrum in 10 EU countries. Dr Germaine Hanquet, EpiConcept, Brussels
- Maximising the potential of PCV through smart scheduling. Dr Shamez Ladhani, PHE
- Possible timelines/ impact of higher valence vaccines and developments on protein vaccines. Dr Mark Alderson, PATH and Dr Richard Malley, Harvard Medical School